However, recent news represents a setback for Novavax's combined vaccine candidate. The U.S. Food and Drug Administration ...

As the COVID virus continues to evolve, experts in respiratory diseases recommend that everyone ages 6 months and older ...

Even previous versions of the vaccine built from XEC’s predecessors like omicron might not be as effective against the new ...

The XEC variant of Covid is quickly becoming the dominant strain of the winter, but the current vaccines may not be as ...

Europe’s drug regulator recommended two novel vaccines for influenza alongside updated composition for two COVID-19 vaccines ...

COVID has changed so much from the first few years of the pandemic, when people got those first vaccines in 2021,” said Dr. Doug Pogue, president of BJC Medical Group.

In a new study examining people with opioid or alcohol use disorder, prescriptions for Ozempic, Wegovy, Mounjaro, and ...

A strain of influenza appears to have disappeared from the planet since COVID. As a result, U.S. flu vaccines have been ...

Shares of US protein-based vaccine maker Novavax closed down 19.4% at $10.15 yesterday having dropped as much as 24%, on the ...

After a lengthy COVID-19 surge this summer, the Bay Area is about to enter the winter respiratory virus season. Explore our ...

The report involved motor neuropathy in a participant of the phase 2 trial conducted outside the U.S., according to an Oct. 16 news release from the company. The participant received the vaccine in ...

Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.